These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 14612002)
1. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Dominguez J; Kompatzki A; Foradori A; Norambuena R Transplant Proc; 2003 Nov; 35(7):2522-3. PubMed ID: 14612002 [TBL] [Abstract][Full Text] [Related]
2. Limited utility of cyclosporine C2 monitoring in heart transplant recipients receiving ketoconazole. Zakliczynski M; Krynicka A; Szewczyk M; Wojarski J; Zembala M Transplant Proc; 2003 Sep; 35(6):2333-4. PubMed ID: 14529932 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668 [TBL] [Abstract][Full Text] [Related]
4. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
5. [Combination of cyclosporin and ketoconazole in immunosuppression schemes in patients with transplanted kidney]. Treĭvish VS; Shoĭkhet IN; Ankova EV Klin Med (Mosk); 1998; 76(1):40-2. PubMed ID: 9532915 [TBL] [Abstract][Full Text] [Related]
6. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Kahan BD; Welsh M; Schoenberg L; Rutzky LP; Katz SM; Urbauer DL; Van Buren CT Transplantation; 1996 Sep; 62(5):599-606. PubMed ID: 8830822 [TBL] [Abstract][Full Text] [Related]
7. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes. Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268 [No Abstract] [Full Text] [Related]
8. Importance of early adequate exposure to cyclosporine in renal transplant outcome: study of 1-year creatinine. Dominguez J; Kompatzki A; Velasco A; Turpaud F; Norambuena R; Arenas J; Pais E; Llanos R; Cortes-Monroy G Transplant Proc; 2005 Oct; 37(8):3358-60. PubMed ID: 16298595 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients. Kabasakul SC; Clarke M; Kane H; Karsten J; Clark G Pediatr Nephrol; 1997 Jun; 11(3):318-21. PubMed ID: 9203180 [TBL] [Abstract][Full Text] [Related]
10. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452 [TBL] [Abstract][Full Text] [Related]
12. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545 [TBL] [Abstract][Full Text] [Related]
13. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Qazi YA; Forrest A; Tornatore K; Venuto RC Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147 [TBL] [Abstract][Full Text] [Related]
14. Evolution of the therapeutic drug monitoring of cyclosporine. Citterio F Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378 [TBL] [Abstract][Full Text] [Related]
15. Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients. Kelles A; Van Damme-Lombaerts R; Tjandra-Maga TB; Van Damme B Transpl Int; 1996; 9(6):546-50. PubMed ID: 8914233 [TBL] [Abstract][Full Text] [Related]
17. Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. Kokuhu T; Fukushima K; Ushigome H; Yoshimura N; Sugioka N Int J Med Sci; 2013; 10(12):1665-73. PubMed ID: 24151438 [TBL] [Abstract][Full Text] [Related]
19. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244 [No Abstract] [Full Text] [Related]
20. Conversion of cyclosporine A to tacrolimus following heart transplantation. Mathieu P; Carrier M; White M; Pellerin M; Perrault LP; Pelletier G; Pelletier LC Can J Cardiol; 1999 Nov; 15(11):1229-32. PubMed ID: 10579737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]